To investigate the effect of endometrial thickness on the clinical outcome of cleavage embryo HRT-FET on the day of embryo transfer and analyzed the threshold and optimal thickness interval corresponding to ideal clinical pregnancy rate by statistical method. A total of 5861 HRT-FET cycles with cleavage embryo transferred from January 2013 to December 2017 in the Reproductive Medicine Center of Henan Provincial People's Hospital were studied retrospectively．Fifth-order grouping of endometrial thickness (EMT) on embryo transfer day as a continuous variable by statistical software, they were divided into five subgroups Q1 (EMT4.0-7.9 mm), Q2 (EMT 8.0-8.9 mm), Q3 (EMT 9.0-9.5 mm), Q4 (EMT 9. 6-10.9 mm), Q5 (EMT 11.0-19.0 mm). After adjusting for confounding factors, the clinical pregnancy rate and live birth rate in other groups were higher than Group Q1 significantly (p  less then  .05). The cutoff value of the endometrial thickness was 8.6 mm, When endometrial thickness was less than 8.6 mm, with each additional 1 mm of endometrial thickness, clinical pregnancy rate increased by 49% (OR = 1.49, 95%CI (1.35, 1.66), p  less then  .001), the live birth rate increased by 59% (OR= 1.59, 95%CI (1.42, 1.78), p  less then  .001), When the endometrial thickness was thicker than the threshold, clinical pregnancy rate (OR = 1.02, 95%CI (0.97, 1.07), p = .398) and the live birth rate (OR = 1.00, 95%CI (0.96, 1.05), p = .398) remained stable. In the cleavage embryo HRT-FET cycle, endometrial thickness is a curvilinear relationship with clinical outcome, the optimal endometrial thickness interval for ideal clinical outcome was 8.6-15mm.Purpose Until now, three cases of growth of an orbital schwannoma during pregnancy have been published. We aim to provide additional insight in the effect of pregnancy on orbital schwannomas.Methods We present two additional cases of accelerated growth of orbital schwannomas during pregnancy and investigate receptor expression profiles for estrogen, progesterone, androgen, VEGF, EGF, FGF, PDGF-Rβ and ki-67 in the two pregnant cases and six non-pregnant cases.Results Case 1 A 26-year-old woman developed unilateral exophthalmos during pregnancy, with normal visual acuity and ocular motility. During a subsequent pregnancy, again the exophthalmos progressed. MRI showed a mass suggestive of schwannoma. After delivery, resection of the lesion was performed through an anterior approach. Pathology confirmed schwannoma. The expression profile was positive for estrogen- and FGF receptors and ki-67, but negative for progesterone-, androgen- and other growth factor receptors. Solutol HS-15 research buy Case 2 A 24-year-old woman presented with diplopia and unilateral pain during pregnancy. She had normal visual acuity, but a mild exophthalmos and elevation deficit. MRI revealed an extraconal mass suggestive of schwannoma. After delivery, resection was performed through an anterior approach. Pathology confirmed the diagnosis. The expression profile was positive for ki-67, but negative for sex hormone- and growth factor receptors.In the six non-pregnant cases the expression profiles varied, with only one subject showing a strong expression of estrogen-, progesterone- and androgen receptors.Conclusions Orbital schwannomas can experience growth during pregnancy. The underlying mechanism remains unclear as hormone- and growth factor expression profiles show no correlation to the pregnant state.FF-10501-01 potently inhibits inosine-5-monophosphate dehydrogenase (IMPDH), inducing anti-proliferative and pro-apoptotic effects in acute myeloid leukemia (AML) human cell lines resistant to hypomethylating agents. In this Phase 1/2a study, Phase 1 enrolled 38 patients with relapsed/refractory AML (n = 28) or myelodysplastic syndromes (MDS/CMML, n = 10) to receive FF-10501 oral doses 50-500 mg/m2 BID for 14 or 21 days out of each 28-day cycle. Fifteen additional patients with HMA-resistant MDS/CMML (Phase 2a) were treated at 400 mg/m2 BID for 21 days. Most Phase 1 adverse events were disease-related and low-grade. 3 of 19 (16%) evaluable AML patients achieved partial remission (31, 7, and 5 months). 2 of 20 (10%) evaluable MDS/CMML patients (Phase 1 and 2a) attained marrow complete remission, one continuing treatment for 17 months. While FF-10501-01 demonstrated clinical activity and target inhibition in heavily pretreated patients with AML and MDS/CMML, increased mucositis events led to Phase 2a closure (ClinTrials.gov#NCT02193958).Introduction Natural, social, and constructed environments play a critical role in the development and exacerbation of respiratory diseases. However, less is known regarding the influence of these environmental/community risk factors on the health of individuals living with cystic fibrosis (CF), compared to other pulmonary disorders.Areas Covered Here, we review current knowledge of environmental exposures related to CF, which suggest that environmental/community risk factors do interact with the respiratory tract to affect outcomes. Studies discussed in this review were identified in PubMed between March 2019 and March 2020. Although the limited data available do not suggest that avoiding other potentially detrimental exposures could improve outcome, additional research incorporating novel markers of environmental exposures and community characteristics obtained at localized levels is needed.Expert Opinion As we outline, some environmental exposures and community characteristics are modifiable; if not by the individual, then by policy. We recommend a variety of strategies to advance understanding of environmental influences on CF disease progression.Nearly all diseases in humans, to a certain extent, exhibit sex differences, including differences in the onset, progression, prevention, therapy, and prognosis of diseases. Accumulating evidence shows that macroautophagy/autophagy, as a mechanism for development, differentiation, survival, and homeostasis, is involved in numerous aspects of sex differences in diseases such as cancer, neurodegeneration, and cardiovascular diseases. Advances in our knowledge regarding sex differences in autophagy-mediated diseases have enabled an understanding of their roles in human diseases, although the underlying molecular mechanisms of sex differences in autophagy remain largely unexplored. In this review, we discuss current advances in our insight into the biology of sex differences in autophagy and disease, information that will facilitate precision medicine.Abbreviations AD Azheimer disease; AMBRA1 autophagy and beclin 1 regulator 1; APP amyloid beta precursor protein; AR androgen receptor; AMPK AMP-activated protein kinase; ATG autophagy related; ATP6AP2 ATPase H+ transporting accessory protein 2; BCL2L1 BCL2 like 1; BECN1 beclin 1; CTSD cathepsin D; CYP19A1 cytochrome P450 family 19 subfamily A member 1; DSD disorders of sex development; eALDI enhancer alternate long-distance initiator; ESR1 estrogen receptor 1; ESR2 estrogen receptor 2; FYCO1 FYVE and coiled-coil domain autophagy adaptor 1; GABARAP GABA type A receptor-associated protein; GLA galactosidase alpha; GTEx genotype-tissue expression; HDAC6 histone deacetylase 6; I-R ischemia-reperfusion; LAMP2 lysosomal associated membrane protein 2; MAP1LC3B/LC3B microtubule associated protein 1 light chain 3 beta; MTOR mechanistic target of rapamycin kinase; m6A N6-methyladenosine; MYBL2 MYB proto-oncogene like 2; PIK3C3 phosphatidylinositol 3-kinase catalytic subunit type 3; PSEN1 presenilin 1; PSEN2 presenilin 2; RAB9A, RAB9A member RAS oncogene family; RAB9B, RAB9B member RAS oncogene family; RAB40AL RAB40A like; SF1 splicing factor 1; SOX9 SRY-box transcription factor 9; SRY sex determining region Y; TFEB transcription factor EB; ULK1 unc-51 like autophagy activating kinase 1; UVRAG UV radiation resistance associated; VDAC2 voltage dependent anion channel 2; WDR45 WD repeat domain 45; XPDS X-linked parkinsonism and spasticity; YTHDF2 YTH N6-methyladenosine RNA binding protein 2.